Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RPRX Stock Forecast 2025-2026
$39.73
Current Price
$23.17B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RPRX Price Targets
+41.0%
To High Target of $56.00
+5.7%
To Median Target of $42.00
-4.4%
To Low Target of $38.00
RPRX Price Momentum
-0.7%
1 Week Change
+3.0%
1 Month Change
+53.3%
1 Year Change
+55.7%
Year-to-Date Change
-3.7%
From 52W High of $41.24
+65.2%
From 52W Low of $24.05
📊 TOP ANALYST CALLS
Did RPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Royalty Pharma is one of their latest high-conviction picks.
Latest RPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, RPRX has a bullish consensus with a median price target of $42.00 (ranging from $38.00 to $56.00). The overall analyst rating is N/A (N/A/10). Currently trading at $39.73, the median forecast implies a 5.7% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Geoff Meacham at B of A Securities, suggesting a 4.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPRX Analyst Ratings
8
Buy
1
Hold
0
Sell
RPRX Price Target Range
Low
$38.00
Average
$42.00
High
$56.00
Current: $39.73
Latest RPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Sep 30, 2025 | Goldman Sachs | Asad Haider | Buy | Initiates | $42.00 |
| Jul 22, 2025 | Citigroup | Geoff Meacham | Buy | Maintains | $42.00 |
| Jul 10, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Oct 25, 2024 | Citigroup | Andrew Baum | Buy | Maintains | $40.00 |
| Aug 14, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $51.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $51.00 |
| Jun 3, 2024 | UBS | Ashwani Verma | Neutral | Downgrade | $28.00 |
| Apr 12, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $38.00 |
| Feb 20, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $50.00 |
| Feb 20, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $42.00 |
| Nov 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $57.00 |
| Oct 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $54.00 |
| Aug 9, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $53.00 |
| Jul 11, 2023 | Morgan Stanley | Terence Flynn | Overweight | Reiterates | $52.00 |
| May 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $52.00 |
| Apr 10, 2023 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $50.00 |
| Apr 10, 2023 | Tigress Financial | Buy | Reiterates | $N/A | |
| Apr 6, 2023 | Tigress Financial | Ivan Feinseth | Buy | Reiterates | $60.00 |
| Feb 16, 2023 | UBS | Ashwani Verma | Buy | Maintains | $48.00 |
Royalty Pharma plc (RPRX) Competitors
The following stocks are similar to Royalty Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RPRX
Royalty Pharma
mkt cap
23.17B
Royalty Pharma plc (RPRX) Financial Data
Royalty Pharma plc has a market capitalization of $23.17B with a P/E ratio of 22.4x. The company generates $2.35B in trailing twelve-month revenue with a 32.6% profit margin.
Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of +70.3% and return on equity of +13.1%.
Valuation Metrics
Market Cap
$23.17B
Enterprise Value
$27.94B
P/E Ratio
22.4x
PEG Ratio
-0.5x
Price/Sales
9.7x
Growth & Margins
Revenue Growth (YoY)
+7.9%
Gross Margin
N/A
Operating Margin
+70.3%
Net Margin
+32.6%
EPS Growth
-47.0%
Financial Health
Cash/Price Ratio
+5.6%
Current Ratio
3.5x
Debt/Equity
93.2x
ROE
+13.1%
ROA
+5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Royalty Pharma plc (RPRX) Business Model
About Royalty Pharma plc
What They Do
Acquires biopharmaceutical royalties for funding innovation.
Business Model
Royalty Pharma generates revenue by purchasing royalties from drug developers, providing them with immediate capital. This funding supports research and development efforts within the pharmaceutical sector, allowing developers to focus on creating new therapies while Royalty Pharma collects a share of the revenue generated from successful drug sales.
Additional Information
The company boasts a diversified portfolio that spans various therapeutic areas, including oncology, neurology, and rare diseases. This diversification helps mitigate risks and enhances potential returns. Royalty Pharma's sustainable financing model plays a crucial role in promoting innovation in the healthcare market, benefiting patients and investors alike.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Pablo Gerardo Legorreta
Country
United States
IPO Year
2020
Website
www.royaltypharma.comRoyalty Pharma plc (RPRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Denali Enters Into a $275M Funding Deal With Royalty Pharma
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Dec 05, 2025
By Ekta Bagri
Analyst Blog
Latest News
Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
4 days ago
Quick Summary
Royalty Pharma plc (RPRX) presented at the Citi Annual Global Healthcare Conference 2025, providing insights into its business and strategies.
Why It Matters
Royalty Pharma's presentation at a major healthcare conference could highlight growth opportunities, partnerships, or financial performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
3 days ago
Quick Summary
Royalty Pharma plc (RPRX) presented at the Evercore 8th Annual Healthcare Conference, discussing its business and financial strategies.
Why It Matters
Royalty Pharma's presentation may highlight strategic initiatives, financial performance, or new partnerships, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma and Denali Therapeutics have entered a $275 million synthetic royalty funding agreement linked to future net sales of tividenofusp alfa.
Why It Matters
The $275 million funding agreement indicates confidence in tividenofusp alfa's market potential, potentially boosting both companies' valuations and signaling growth opportunities in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Denali Therapeutics and Royalty Pharma announced a $275 million synthetic royalty funding agreement tied to future sales of tividenofusp alfa.
Why It Matters
The $275 million synthetic royalty agreement indicates confidence in tividenofusp alfa's market potential, potentially boosting both companies' valuations and influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma plc (Nasdaq: RPRX) will participate in several investor conferences in December 2025.
Why It Matters
Royalty Pharma's participation in investor conferences can signal potential growth opportunities and increased visibility, impacting stock sentiment and investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Royalty Pharma is rated a Buy following strong Q3 results and raised guidance. It trades at a discount to peers, with robust free cash flow and ongoing buybacks and new deals.
Why It Matters
Royalty Pharma's strong Q3 results and raised guidance indicate growth potential. Its discounted valuation relative to peers and ongoing buybacks suggest an attractive investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About RPRX Stock
What is Royalty Pharma plc's (RPRX) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Royalty Pharma plc (RPRX) has a median price target of $42.00. The highest price target is $56.00 and the lowest is $38.00.
Is RPRX stock a good investment in 2026?
According to current analyst ratings, RPRX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $39.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPRX stock?
Wall Street analysts predict RPRX stock could reach $42.00 in the next 12 months. This represents a 5.7% increase from the current price of $39.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Royalty Pharma plc's business model?
Royalty Pharma generates revenue by purchasing royalties from drug developers, providing them with immediate capital. This funding supports research and development efforts within the pharmaceutical sector, allowing developers to focus on creating new therapies while Royalty Pharma collects a share of the revenue generated from successful drug sales.
What is the highest forecasted price for RPRX Royalty Pharma plc?
The highest price target for RPRX is $56.00 from at , which represents a 41.0% increase from the current price of $39.73.
What is the lowest forecasted price for RPRX Royalty Pharma plc?
The lowest price target for RPRX is $38.00 from Geoff Meacham at B of A Securities, which represents a -4.4% decrease from the current price of $39.73.
What is the overall RPRX consensus from analysts for Royalty Pharma plc?
The overall analyst consensus for RPRX is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are RPRX stock price projections?
Stock price projections, including those for Royalty Pharma plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:14 AM UTC